Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS1304 Combined With Endocrine Therapy in ER+/HER2- Breast Cancer
NCT07235176Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLS1304 in breast cancer, sponsored by Qilu Pharmaceutical. Started Jan 2026; status: recruiting.
02
Drugs
QLS1304
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07235176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235176.